NCT07272603Not yet recruitingEarly phase 1
Bladder Perfusion of Plasma-Activated Saline for Bladder Cancer
Preliminary Clinical Study Evaluating the Therapeutic Response and Safety of Intravesical Perfusion With Plasma-Activated Saline Solution in Patients With Bladder Cancer
Source: ClinicalTrials.gov · Last updated 9 Dec 2025
Brief summary (registry, in English)
This preliminary clinical study evaluates the safety and initial efficacy of a novel therapy called Plasma-Activated Saline Solution (PASS) for bladder cancer patients. The study involves a one-week course of PASS administered via bladder infusion in five pre-surgical patients, using imaging and pathology analyses to assess tumor shrinkage and cancer cell death, while closely monitoring for any adverse reactions to explore the therapy's future potential.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- First submitted
- 26 Nov 2025
- Start date
- 15 Dec 2025
- Primary completion date
- 15 Feb 2026
- Lead sponsor
- Qilu Hospital of Shandong University
- Diseases
- Bladder cancer
- NCT number
- NCT07272603
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 5
- From 15 Dec 2025 to the primary completion date, 15 Feb 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of severe comorbidities, including but not limited to cardiac disease, severe hepatic or renal insufficiency, uncontrolled hypertension, or diabetes.
- Active urinary tract infection or a functional bladder capacity of less than 200 mL.
- History of other malignancies.
- Any other condition deemed by the investigator to make the patient unsuitable for study participation.
Other
- Pregnancy or lactation.
- Poor compliance, assessed as unlikely to complete the trial per protocol requirements.
Who the study is looking for
- Patients with a pathological diagnosis of bladder cancer.
- Patients scheduled for radical cystectomy, with at least one measurable tumor lesion ≥10 mm in diameter.
- Age between 18 and 75 years.
- Treatment-naïve patients who have not received any prior therapy for bladder cancer.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.